Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Issue Section
Date
Availability
1-2 of 2
Keywords: Steroid therapy
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Subject Area:
Oncology
Yoshikazu Toshima, Keiki Yokoo, Koki Kamata, Takayuki Nagao, Satoshi Ota, Gen Yamada, Hirofumi Chiba
Journal:
Case Reports in Oncology
Case Rep Oncol (2025) 18 (1): 794–799.
Published Online: 15 May 2025
... Immune-checkpoint inhibitors Immune-related adverse event Lung adenocarcinoma Pembrolizumab Steroid therapy Immune-checkpoint inhibitors (ICIs), such as pembrolizumab, are the standard treatment for stage IV non-small cell lung cancer. In cases with high programmed death-ligand 1 (PD-L1...
Journal Articles
Subject Area:
Oncology
Senichiro Yanagawa, Nozomi Karakuchi, Tetsuya Mochizuki, Shinya Kodama, Yukio Takeshima, Kazuo Sumimoto
Journal:
Case Reports in Oncology
Case Rep Oncol (2020) 13 (2): 768–773.
Published Online: 02 July 2020
... and a curative treatment is yet to be established. DI-IP due to chemotherapy is most commonly observed in patients treated with mitomycin, paclitaxel, docetaxel, or gemcitabine. Steroid therapy is mostly used to treat DI-IP, although the efficacy of such treatments is not supported with adequate evidence. FOLFOX...